Hugel
Quick facts
Marketed products
- Botulinum toxin type A injection · Neurology; Aesthetics; Dermatology
Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. - Botulinum Toxin Type A Injection [Botox]
Phase 3 pipeline
- Botulinum Toxin Type A Injection [HG102] · Neurology; Aesthetics; Pain Management
Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. - Hugeltox · Other
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Hugel
What are Hugel's marketed drugs?
Top marketed products include Botulinum toxin type A injection, Botulinum Toxin Type A Injection [Botox].
What is Hugel's pipeline?
Hugel has 2 drugs in Phase 3, 0 in Phase 2, 1 in Phase 1. Late-stage candidates include Botulinum Toxin Type A Injection [HG102], Hugeltox.
Related
- Botulinum toxin type A injection · Neurology; Aesthetics; Dermatology
- Botulinum Toxin Type A Injection [Botox]
- Sector hub: All tracked pharma companies